Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma
| Autor: | Natale Cascinelli, M. T. Baldini, Luigi Mascheroni, Rosaria Bufalino, Caudio Clemente, Martin C. Mihm, S. Zurrida |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty Skin Neoplasms CD3 Complex Metastatic melanoma Dermatology Placebo Injections Double-Blind Method medicine Humans Thymopentin In patient Melanoma Sclerosis business.industry medicine.disease Lymphocyte Subsets Cytolysis Oncology Leukocyte Common Antigens business Minor Response medicine.drug Lymphocyte subsets |
| Zdroj: | Melanoma Research. 3:471-476 |
| ISSN: | 0960-8931 |
| Popis: | The potential therapeutic efficacy of TP5 in patients with cutaneous and subcutaneous metastases of melanoma was tested in a double-blind study comparing the drug and placebo injected perinodularly. Of the 47 nodules present in the 16 patients treated with TP5, 24 showed a measurable response, whereas only one out of 15 nodules in patients treated with a placebo showed a minor response (P = 0.02). In two patients treated with TP5 a response of two nodules not perinodularly injected was also observed. Sclerosis, CD45RO+ cells and MIB 1- cells were more frequently observed in nodules treated with TP5 than with placebo. (P = 8 x 10(-4); 0.03 and 0.01, respectively). Evaluating the trends of these findings in nodules treated with placebo; with TP5-treated, non-responding nodules; or with TP5-treated, responding, a positive trend was observed for sclerosis and CD45RO+ cells (P = 5 x 10(-4) and 2 x 10(-3), respectively) and a negative one for MIB 1 cells (P = 2 x 10(-3)). These preliminary data suggest that lymphoid cells associated with nodules regression are activated large lymphocytes (CD45RO+ and CD3-). Sclerosis might be interpreted as the final morphologic event, and reduction of proliferative activity (MIB 1- cells) as the consequence of cytolytic action. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|